排序方式： 共有3条查询结果，搜索用时 15 毫秒
1
1.
The present study was carried out to evaluate the antidiabetic effect of T. arjuna stembark extract and to study the activities
of hexokinase, aldolase and phosphoglucoisomerase, and gluconeogenic enzymes such as glucose-6-phosphatase and fructose-1,6-diphosphatase
in liver and kidney of normal and alloxan induced diabetic rats. Oral administration of ethanolic extract of bark (250 and
500mg/kg body weight) for 30 days, resulted in significant decrease of blood glucose from 302.67±22.35 to 82.50±04.72 and
in a decrease in the activities of glucose-6-phosphatase, fructose-1,6-disphosphatase, aldolase and an increase in the activity
of phosphoglucoisomerase and hexokinase in tissues. However, in the case of 250 mg/kg body weight of extract, less activity
was observed. The study clearly shows that the bark extract ofT. arjuna possesses potent antidiabetic activity. 相似文献
2.
Najma Zaheer Baquer Dhananjay Gupta Jayadev Raju 《Indian journal of clinical biochemistry : IJCB》1998,13(2):63-80
Diabetes has been classified as a disease of glucose overproduction by tissues, mainly liver and glucose underutilization
by insulin requiring tissues like liver, adipose and muscle due to lack of insulin. There is, however, glucose over utilization
in tissues not dependent on insulin for glucose transport like kidney, nerve and brain. There are serious complications due
to this excess glucose in these tissues and their reversal is important for a good metabolic control and normalisation of
other parameters. Insulin, trace metals and some plant extracts have been used to see the reversal effects of the complications
of diabetes in liver and kidney in experimental diabetes. Almost complete reversal of the metabolic changes has been achieved
in the activities of key enzymes of metabolic pathways in liver and kidney and an effective glucose control has been achieved
suggesting a combination of therapies in the treatment of metabolic disturbance of the diabetic state. 相似文献
3.
Sabina Semiz Tanja Dujic Adlija Causevic 《Biochemia medica : ?asopis Hrvatskoga dru?tva medicinskih biokemi?ara / HDMB》2013,23(2):154-171
Type 2 diabetes mellitus (T2DM) is a worldwide epidemic with considerable health and economic consequences. T2DM patients are often treated with more than one drug, including oral antidiabetic drugs (OAD) and drugs used to treat diabetic complications, such as dyslipidemia and hypertension. If genetic testing could be employed to predict treatment outcome, appropriate measures could be taken to treat T2DM more efficiently. Here we provide a review of pharmacogenetic studies focused on OAD and a role of common drug-metabolizing enzymes (DME) and drug-transporters (DT) variants in therapy outcomes. For example, genetic variations of several membrane transporters, including SLC22A1/2 and SLC47A1/2 genes, are implicated in the highly variable glycemic response to metformin, a first-line drug used to treat newly diagnosed T2DM. Furthermore, cytochrome P450 (CYP) enzymes are implicated in variation of sulphonylurea and meglitinide metabolism. Additional variants related to drug target and diabetes risk genes have been also linked to interindividual differences in the efficacy and toxicity of OAD. Thus, in addition to promoting safe and cost-effective individualized diabetes treatment, pharmacogenomics has a great potential to complement current efforts to optimize treatment of diabetes and lead towards its effective and personalized care. 相似文献
1